Acquisition of Verona by MSD Approved by the High Court of Justice of England and Wales

Core Viewpoint - Verona Pharma plc has entered into a definitive agreement for its acquisition by MSD (Merck & Co., Inc.) at a price of $107 per American Depository Share (ADS), totaling approximately $10 billion for the transaction [1][2]. Group 1: Transaction Details - The acquisition will be executed through a Court-sanctioned scheme of arrangement under English law, which has been approved by the High Court of Justice of England and Wales [2]. - The closing of the transaction is expected to occur on October 7, 2025, with trading of Verona ADSs on Nasdaq halting before the market opens on that date [3]. Group 2: Company Overview - Verona Pharma is a biopharmaceutical company focused on developing innovative therapies for chronic respiratory diseases with significant unmet medical needs [5].